[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557813":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":19,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Anhui Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"rTMS group","EXPERIMENTAL","On the basis of drug treatment, a course of TBS treatment is performed for 7 days.",[13],"Other: transcranial magnetic stimulation",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"transcranial magnetic stimulation","During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Kai Wang, Ph.D.","CONTACT","055162923704","wangkai1964@126.com",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Panpan Hu, M.D.","13515602285","hpppanda9@126.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":19,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Cognitive Neuropsychology Lab Anhui Medical University","RECRUITING","Hefei","Anhui","China",{"type":38,"coordinates":39},"Point",[40,41],117.28083,31.86389,{"lat":41,"lon":40},[44,46],{"name":22,"role":23,"phone":45,"phoneExt":19,"email":25},"+8655162923704",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","WANG KAI","Head, Dept of Neurology & Medical Psychology, Director, Cognitive Neuropsychology Lab, PRC","100557813",false,"NCT06542991","An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD","Inclusion Criteria:\n\n1. Age ≥40 years old\n2. Meet Movement Disorder Society standards;\n3. Have no history of drug adjustment within 4 weeks before and during treatment;\n4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4\n5. MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.\n\nExclusion Criteria:\n\n1. Head MRI\u002FCT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);\n2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);\n3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;\n4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.\n5. The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;\n6. Diagnosed with a neuropsychiatric disorder other than PD\n7. Have a history of drug abuse or drug use;\n8. Participants in any clinical trial within the previous 6 month;\n9. Pregnant\u002Flactating women or subjects (including men) who have a birth plan within 6 months;\n10. Other conditions deemed unsuitable for inclusion by the investigator.","ALL","40 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"NA","To demonstrate that intervention targeting the supplementary motor area (SMA) using precise navigation positioning can effectively improve motor symptoms in patients with Parkinson's disease.",[66,67,68],"Transcranial Magnetic Stimulation","Parkinson Disease","Supplementary Motor Area",[66,67,70],"Supplementary motor area","2024-08-03",{"date":73,"type":74},"2024-08-07","ACTUAL",{"date":76,"type":60},"2024-09-01",{"date":78,"type":60},"2025-03-31",{"name":5,"class":6},1]